This Month
Barrenjoey, Morgans test IPO appetite for $100m-plus Tetratherix
In the lead-up to the IPO, Tetratherix has tapped Emma Cleary – a former CFO of Navis Capital’s $1.5 billion Device Technologies – to chair its board.
The Aussie bringing Black Mirror-esque brain tech to reality
This neurologist has built technology allowing humans to control machines with just their thoughts. Now he’s racing Tesla’s founder to take it to the masses.
Biotech Dimerix lands $940m licensing deal for kidney drug sales
The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.
Wentworth buys $200m asset for $1.5b BlackRock life sciences JV
The North Ryde deal comes after Wentworth in 2023 struck a deal with Sydney University to develop a $500 million life sciences hub.
April
Diagnostics company BlinkLab seeks funds ahead of FDA submission
Street Talk understands the ASX-listed company’s stockbrokers Alpine Capital and Westar Capital will launch a $5 million single-tranche placement on Tuesday morning.
This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
Cochlear-backed Epiminder targets 2025 IPO as FDA authorisation lands
E&P Capital, which helped Epiminder raise funds this year, will lead the bookbuild alongside Morgans.
How this $115b ASX giant plans to win from both sides of the trade war
On the front line of the tit-for-tat tariff fight between the US and China, Australian companies are trying to find a way to play both sides.
Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc
Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.
Teal corflute bandit could have been a medtech star
Peter Jordan’s timing at leaving dud businesses is better than his ability to get away from scenes of election poster shenanigans.
Phil King’s Regal writes Opthea to zero and backs off risky bets
The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ensure it does not occur again”.
March
Opthea in active talks with funders after second trial fails
The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye disease treatment had failed.
TPG Capital seals $3b-plus Novotech sale with Singapore’s GIC, Temasek
The two sovereign wealth funds have taken a “significant stake” in the clinical research business owned by the private equity giant for eight years.
The clinical trial result from hell has biotech investors on edge
From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.
Pengana freezes fund redemptions as it braces for big Opthea loss
The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has warned it could be insolvent.
Regal’s listed funds slash value of biotech Opthea by two-thirds
The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It is the company’s largest investor.
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play that could become insolvent after a poor medical result.
Imricor Medical Systems passes can around for $80m, Morgans on ticket
The ASX-listed medtech began wall-crossing investors over the weekend, seeking support for an equity raising of as much as $80 million.
OneVentures-backed artificial heart start-up rattles the tin for $100m
BiVACOR has made the world’s first titanium heart and is hoping to manufacture the device commercially in Australia and the US within three years.
David Williams says he makes no apologies for ‘aggressive’ style
The outspoken investment banker is the chairman of PolyNovo. The burns treatment company’s chief executive is leaving after a falling out with the board.